Biogen Idec Inc (BIIB) 269.16 $BIIB Biogen, Roche &

New Post Public Reply Private Reply Replies (0) Message Board

Oct 9, 2015 at 8:24 PM

Biogen Idec Inc (BIIB) 269.16 $BIIB

Biogen, Roche & Novartis Present Data on MS Drugs in Spain
Zacks Equity Research - Zacks Investment Research - 2 hrs 58 mins ago
Quite a few pharma/biotech companies presented encouraging data on their multiple sclerosis (MS) candidates at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS).
BIIB: 269.16 (-10.72), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)

Plenty of Good News -- If You Look
at The Street - Fri Oct 09, 2:13PM CDT
Not all growth is hated today.
AMZN: 539.80 (+6.64), BIIB: 269.16 (-10.72), MCK: 189.95 (+3.66), DAL: 47.21 (+1.25), UNH: 119.27 (+3.19), GOOG: 643.61 (+4.45), UAL: 55.71 (+3.45), WWAV: 43.82 (+2.11), AGN: 274.84 (-1.32), WDAY: 77.57 (+1.71), DPZ: 105.38 (+2.74), TEVA: 58.96 (-0.28), GOOGL: 671.24 (+4.24), ULTA: 165.80 (+1.86), REGN: 503.92 (+12.71)

Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)

Biogen Announces Departure of Tony Kingsley
Business Wire - Fri Oct 09, 6:30AM CDT
Biogen (NASDAQ: BIIB) today announced that Tony Kingsley, executive vice president, Global Commercial Operations, will leave the company and a search has been initiated for a permanent replacement. In the interim his responsibilities will be assumed by John G. Cox, executive vice president, Pharmaceutical Operations & Technology.
BIIB: 269.16 (-10.72)

'Fast Money' Recap: Avoid Alcoa on Its Disappointing Earnings
at The Street - Fri Oct 09, 4:00AM CDT
The trading panel discussed biotech stocks and Netflix' subscription rate increase.
NFLX: 113.33 (-1.60), BIIB: 269.16 (-10.72), AA: 10.26 (-0.75), SPY: 201.33 (+0.12), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RGLS: 6.86 (+0.29), CELG: 117.38 (-0.59)

BioMed Realty Just One of Blackstone's Latest Multi-Billion-Dollar Deals
at The Street - Thu Oct 08, 12:02PM CDT
Blackstone's $8 billion deal for the life-science-focused real estate company, BioMed, is the latest in a string of REIT acquisitions.
BIIB: 269.16 (-10.72), GE: 28.07 (+0.04), BMR: 23.40 (-0.05), BX: 34.12 (+0.11), BEE: 14.02 (unch), WFC: 52.14 (-0.40)

GPM Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. Investors
Business Wire - Thu Oct 08, 9:30AM CDT
Glancy Prongay & Murray LLP ("GPM"

announces the filing of a class action lawsuit on behalf of investors of Biogen, Inc. ("Biogen" or the "Company"

(NASDAQ:BIIB) who purchased shares between January 29, 2015 and July 23, 2015, inclusive (the "Class Period"

and have been damaged by the recent declines in the Company's stock price. Biogen investors have until October 19, 2015 to file a lead plaintiff motion. Investors with losses of over $1,000,000 are encouraged to contact GPM to discuss their legal rights.
BIIB: 269.16 (-10.72)

Stock Market News for October 08, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session in the green boosted by gains in biotechnology companies
KMI: 32.35 (-0.33), BIIB: 269.16 (-10.72), MON: 89.70 (+0.45), COP: 56.10 (-0.18), AMGN: 149.59 (-0.31), BA: 139.70 (+0.66), CELG: 117.38 (-0.59), LYB: 95.45 (-2.05), GILD: 100.65 (-0.16), DD: 56.18 (+0.05), CVX: 89.57 (-0.34), DOW: 47.08 (-0.71), REGN: 503.92 (+12.71), ECL: 120.54 (+0.01), YUM: 70.25 (+2.79)

Sanofi Unveils New Positive Data on Lemtrada and Aubagio
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 8:30AM CDT
Sanofi (SNY) unveiled positive new data on multiple sclerosis drugs, Lemtrada and Aubagio.
BIIB: 269.16 (-10.72), AZN: 32.23 (-0.16), SNY: 48.75 (+0.03), NVS: 91.90 (-0.71)

Biogen Caused Biotech Collapse but Might Also Lead Stocks Higher
at The Street - Thu Oct 08, 7:49AM CDT
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
BIIB: 269.16 (-10.72), GILD: 100.65 (-0.16), IBB: 308.45 (+1.25), AMGN: 149.59 (-0.31), CELG: 117.38 (-0.59)

Results from ZINBRYTA(TM) (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS
Business Wire - Thu Oct 08, 5:15AM CDT
--a^' Additional Analyses Reinforce Safety Profile of ZINBRYTA a^'
BIIB: 269.16 (-10.72), ABBV: 55.64 (-0.40)

BIOGEN, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Biogen Inc. -- BIIB
GlobeNewswire - Wed Oct 07, 6:00PM CDT
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Biogen Inc. (Nasdaq:BIIB) ("Biogen" or the "Company"

on behalf of purchasers of the Company's securities between January 29, 2015 and July 23, 2015, inclusive (the "Class Period"

.
BIIB: 269.16 (-10.72)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB
GlobeNewswire - Wed Oct 07, 5:26PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc. (NASDAQ:BIIB) securities between January 29, 2015 and July 23, 2015.
BIIB: 269.16 (-10.72)

Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay
Arpita Dutt - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Amgen (AMGN) and Regeneron (REGN) should benefit from Express Scripts' decision to place both their PCSK9 inhibitors on its National Preferred Formulary.
BIIB: 269.16 (-10.72), ONCE: 49.30 (+1.86), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), ACOR: 29.89 (-0.22), FOLD: 7.58 (+0.71), REGN: 503.92 (+12.71)

Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 88.80 (+0.30), BIIB: 269.16 (-10.72), FB: 93.24 (+0.77), XOM: 79.26 (-0.77), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), INTC: 32.14 (-0.38), CELG: 117.38 (-0.59), WWAV: 43.82 (+2.11), MSFT: 47.11 (-0.34), TWTR: 30.85 (+0.53), CVX: 89.57 (-0.34), GIS: 56.61 (+0.13)

Biogen Is Preparing for a 40% Rally in the Next 12 Months
at The Street - Wed Oct 07, 7:26AM CDT
Detailed technical analysis suggests you should pick up shares of Biogen (BIIB) in order to profit from the coming rally in the stock.
BIIB: 269.16 (-10.72)

Here we go again: Earnings season begins with the 3rd consecutive quarter of negative expectations
ESTMZ - Wed Oct 07, 7:16AM CDT
Earnings season for the third quarter of 2015 unofficially kicks off on Thursday when Alcoa reports. Similar to the last two quarters, we head into the season with negative top and bottom-line growth expectations for the S&P 500… but as anyone...
BIIB: 269.16 (-10.72), F: 14.97 (-0.02), AA: 10.26 (-0.75), MON: 89.70 (+0.45), GILD: 100.65 (-0.16), FB: 93.24 (+0.77), STZ: 136.89 (+0.20), GM: 32.95 (-0.48), GOOGL: 671.24 (+4.24), HPQ: 29.30 (+0.12), SNDK: 62.36 (-1.75), YUM: 70.25 (+2.79), PEP: 99.47 (+0.50)

3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Federal Reserve Bank of New York. With the exception of the last couple of weeks, the biotech sector has been a vast outperformer since the Great Recession. The broad-based S&P 500 has pretty much tripled since hitting its lows in...
BIIB: 269.16 (-10.72), VRTX: 110.00 (+0.97), XBI: 64.76 (+1.11), INCY: 105.00 (+1.56)

New Data Show Strong, Sustained Effects of TECFIDERA(R) (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Business Wire - Wed Oct 07, 5:00AM CDT
--a^' Long-Term Efficacy and Safety of TECFIDERA Demonstrated in Six-Year Data from ENDORSE Study a^'
BIIB: 269.16 (-10.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Center Piping Surges With AI Cooling to $4.5B

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

AI Campuses Drive Surge in Power Cable Market

Surge in Data Center Power Cable Demand Walking down the old data center aisle, you'd never imagine so much copper snaking its way into the modern megalith of AI campuses. But here we are, staring at a market projected to leap from USD 1.74 billion in 2025 to a whopping USD 4.72 billion by 2035. That's a compounded annual growth rate (CAGR) of a robust 10.50%, and it’s...

Rocket Companies' Earnings Preview: What's at Stake?

Anticipation Builds Around Rocket's Earnings Call It ain't every day that a company's earnings announcement stirs up interest the way Rocket Companies' (NYSE:RKT) upcoming third-quarter results have. But here we are, just days away from October 29, 2026, when leadership will lay out the cards at 4:30 p.m. ET. This announcement might just be what investors like us need to...

AMTD Digital's Half-Year Results Stir Investor Interest

AMTD Digital Warming Up for a Busy Quarter Some things just catch the wind differently in the market, and when a heavyweight like AMTD Digital starts talking numbers, everybody perks up. They're gearing up to drop their half-year financials, ready to roll out at the stroke of midnight on October 23rd, and investor ears across the globe are pricked for what’s coming down...

Vertice P2P Aims to Transform Procurement Efficiency

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Lunai Bioworks Voluntarily Delists After Equity Snags

Bracing for the Delisting Impact Well, isn't that a familiar tune? Lunai Bioworks Inc., ticking with the symbol NASDAQ:LNAI, is pulling the plug on its Nasdaq listing faster than a kid yanking out a loose tooth. On October 21, 2026, the company's board decided it's cheaper and simpler to step off the dance floor than keep paying for a spot when the music's stopped....

Centrus Energy to Discuss Q3 Earnings on Nov 5 Call

Centrus Energy Prepares for Earnings Call You ever feel that twinge in your gut right before a big disclosure? Well, that's where Centrus Energy’s about to take us as they gear up for their quarterly earnings call. On November 5th, bright and early at 8:30 a.m. Eastern Time, NYSE:LEU will be in the spotlight, laying out its Q3 results for all us nose-to-the-grindstone...

Venture Dock Fosters Global Startup Ecosystems

Venture Dock Connects the Global Startup Dots When it comes down to bridging the gap between promising innovation and commercial success, you'd be hard-pressed to find a better player than Venture Dock. In a world filled with buzzwords and fluff, these guys are socketed deep in the guts of genuine startup development — and they're making waves with their recent...

Beggin' Unveils Festive Treats for Canine Thanksgiving

Dog Treats That Spice Up Thanksgiving Feast Just when you thought Thanksgiving was all about the humans crowding around a table of turkey and stuffing, Beggin' decides to throw the dogs a bone—literally. These guys rolled out their limited-edition holiday treats that’ll probably have your pup sniffin’ the air like it’s the early days of autumn. What's Cookin' In...

PENNVEST Grants $42M for PA Water Upgrades

Big Boost for Pennsylvania's Water Infrastructure The recent announcement about Pennsylvania American Water scoring a $42 million package from PENNVEST feels like a solid win for everyone except complacency. This move is a direct nod to infrastructure sorely needing an upgrade in Lackawanna and Montgomery counties. You'd think these improvements were long overdue with all...